Caseware UK (AP4) 2023.0.135 2023.0.135 2024-04-302024-04-30No description of principal activityThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.2023-05-01false22falsetruefalse 11923886 2023-05-01 2024-04-30 11923886 2022-05-01 2023-04-30 11923886 2024-04-30 11923886 2023-04-30 11923886 c:Director2 2023-05-01 2024-04-30 11923886 d:PlantMachinery 2023-05-01 2024-04-30 11923886 d:PlantMachinery 2024-04-30 11923886 d:PlantMachinery 2023-04-30 11923886 d:PlantMachinery d:OwnedOrFreeholdAssets 2023-05-01 2024-04-30 11923886 d:FurnitureFittings 2023-05-01 2024-04-30 11923886 d:FurnitureFittings 2024-04-30 11923886 d:FurnitureFittings 2023-04-30 11923886 d:FurnitureFittings d:OwnedOrFreeholdAssets 2023-05-01 2024-04-30 11923886 d:ComputerEquipment 2023-05-01 2024-04-30 11923886 d:ComputerEquipment 2024-04-30 11923886 d:ComputerEquipment 2023-04-30 11923886 d:ComputerEquipment d:OwnedOrFreeholdAssets 2023-05-01 2024-04-30 11923886 d:OtherPropertyPlantEquipment 2023-05-01 2024-04-30 11923886 d:OwnedOrFreeholdAssets 2023-05-01 2024-04-30 11923886 d:CurrentFinancialInstruments 2024-04-30 11923886 d:CurrentFinancialInstruments 2023-04-30 11923886 d:CurrentFinancialInstruments d:WithinOneYear 2024-04-30 11923886 d:CurrentFinancialInstruments d:WithinOneYear 2023-04-30 11923886 d:ShareCapital 2024-04-30 11923886 d:ShareCapital 2023-04-30 11923886 d:RetainedEarningsAccumulatedLosses 2024-04-30 11923886 d:RetainedEarningsAccumulatedLosses 2023-04-30 11923886 d:AcceleratedTaxDepreciationDeferredTax 2024-04-30 11923886 d:AcceleratedTaxDepreciationDeferredTax 2023-04-30 11923886 d:TaxLossesCarry-forwardsDeferredTax 2024-04-30 11923886 d:TaxLossesCarry-forwardsDeferredTax 2023-04-30 11923886 d:OtherDeferredTax 2024-04-30 11923886 d:OtherDeferredTax 2023-04-30 11923886 c:FRS102 2023-05-01 2024-04-30 11923886 c:AuditExempt-NoAccountantsReport 2023-05-01 2024-04-30 11923886 c:FullAccounts 2023-05-01 2024-04-30 11923886 c:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 11923886 2 2023-05-01 2024-04-30 11923886 6 2023-05-01 2024-04-30 11923886 e:PoundSterling 2023-05-01 2024-04-30 iso4217:GBP xbrli:pure
Registered number: 11923886






CITY GROUP MEDICAL LIMITED
UNAUDITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024
 












img49ea.png

 
CITY GROUP MEDICAL LIMITED
REGISTERED NUMBER:11923886

BALANCE SHEET
AS AT 30 APRIL 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 4 
3,854
5,407

Investments
 5 
137,893
94,069

  
141,747
99,476

Current assets
  

Debtors: amounts falling due within one year
 6 
-
1,023

Cash at bank and in hand
  
30,889
62,477

  
30,889
63,500

Creditors: amounts falling due within one year
 7 
(11,578)
(9,061)

Net current assets
  
 
 
19,311
 
 
54,439

Total assets less current liabilities
  
161,058
153,915

Provisions for liabilities
  

Deferred tax
  
(2,917)
-

  
 
 
(2,917)
 
 
-

Net assets
  
158,141
153,915


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
158,041
153,815

  
158,141
153,915


Page 1

 
CITY GROUP MEDICAL LIMITED
REGISTERED NUMBER:11923886
    
BALANCE SHEET (CONTINUED)
AS AT 30 APRIL 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 21 October 2024.




................................................
J Ferguson
Director

The notes on pages 3 to 9 form part of these financial statements.

Page 2

 
CITY GROUP MEDICAL LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

1.


General information

City Group Medical Limited is a private company, limited by shares, domiciled in England and Wales. The registered office is Courtenay House, Pynes Hill, Exeter, EX2 5AZ.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

Page 3

 
CITY GROUP MEDICAL LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

2.Accounting policies (continued)

 
2.4

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

 
2.5

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Plant and machinery
-
20%
straight-line
Fixtures and fittings
-
20%
straight-line
Computer equipment
-
33%
straight-line
Other fixed assets
-
20%
straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 4

 
CITY GROUP MEDICAL LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

2.Accounting policies (continued)

 
2.6

Valuation of investments

Investments in listed company shares are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in profit or loss for the period.

 
2.7

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.8

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.9

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.10

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.

Page 5

 
CITY GROUP MEDICAL LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

2.Accounting policies (continued)

 
2.11

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Company's Balance sheet when the Company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Impairment of financial assets

Financial assets are assessed for indicators of impairment at each reporting date. 

Financial assets are impaired when events, subsequent to their initial recognition, indicate the estimated future cash flows derived from the financial asset(s) have been adversely impacted. The impairment loss will be the difference between the current carrying amount and the present value of the future cash flows at the asset(s) original effective interest rate.

If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the profit or loss.

Financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instruments any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other payables, bank loans and other loans are initially measured at their transaction price after transaction costs. When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial.
 
Trade payables are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade payables are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.

Page 6

 
CITY GROUP MEDICAL LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

2.Accounting policies (continued)

 
2.12

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including the directors, during the year was 2 (2023 : 2 )


4.


Tangible fixed assets





Plant and machinery
Fixtures and fittings
Computer equipment
Total

£
£
£
£



Cost or valuation


At 1 May 2023
6,953
1,425
3,341
11,719


Additions
-
-
1,067
1,067



At 30 April 2024

6,953
1,425
4,408
12,786



Depreciation


At 1 May 2023
2,782
901
2,629
6,312


Charge for the year on owned assets
1,391
284
945
2,620



At 30 April 2024

4,173
1,185
3,574
8,932



Net book value



At 30 April 2024
2,780
240
834
3,854



At 30 April 2023
4,171
524
712
5,407

Page 7

 
CITY GROUP MEDICAL LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

5.


Fixed asset investments





Listed investments

£



Cost or valuation


At 1 May 2023
94,069


Additions
30,000


Revaluations
13,824



At 30 April 2024
137,893





6.


Debtors

2024
2023
£
£


Other debtors
-
1,023

-
1,023



7.


Creditors: Amounts falling due within one year

2024
2023
£
£

Corporation tax
-
5,111

Other taxation and social security
7,600
-

Other creditors
2,845
2,871

Accruals and deferred income
1,133
1,079

11,578
9,061


Page 8

 
CITY GROUP MEDICAL LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

8.


Deferred taxation




2024


£






Charged to profit or loss
(2,917)



At end of year
(2,917)

The deferred taxation balance is made up as follows:

2024
2023
£
£


Accelerated capital allowances
(732)
-

Tax losses carried forward
48
-

Unrelieved losses
(2,233)
-

(2,917)
-

 
Page 9